News
The 20th Academic Conference on Laboratory Medicine of the Beijing Medical Association has concluded successfully.
Release Time:
2026-09-08 10:18
Source:
Keeping pace with cutting-edge developments and focusing on clinical applications, the 20th Beijing Medical Association Conference on Laboratory Medicine, co-hosted by the Beijing Branch of the Chinese Medical Association and the Laboratory Medicine Branch of the Beijing Medical Association, concluded successfully from September 4 to 6, 2026, at the Beijing International Hotel Convention Center. This prestigious event brought together experts and colleagues from Beijing and across the country in the field of laboratory medicine. Leading figures in the industry gathered to share an academic feast, drawing on diverse perspectives, broadening their horizons, deepening professional exchanges, and strengthening bonds of camaraderie.
Star product
BIOSINO
BIOSINO showcased its latest innovations at this exhibition, including the BioCyteX flow cytometer (4 lasers, 21 colors), the PATHFAST point-of-care chemiluminescence cardiac biomarker analyzer, as well as a comprehensive suite of adiponectin and other biochemical assay reagents.
The BioCyteX flow cytometer showcased at this event has once again captured industry attention thanks to its outstanding performance. The instrument has undergone a comprehensive upgrade, now supporting up to four lasers and 21 fluorescence channels, with the capability to measure as many as 24 parameters, thereby demonstrating significant advantages in high resolution, high sensitivity, and exceptional stability. Moreover, the BioCyte flow cytometer can be integrated with the AutoProSample A960 to form a fully automated flow‑cytometry workstation, effectively addressing the challenges of automating and standardizing sample preparation for flow cytometry.
The PATHFAST point-of-care cardiac biomarker analyzer delivers rapid results in emergency settings, supporting efficient management of critical and life‑threatening conditions. Since 2018, it has officially partnered with Medience Co., Ltd., formerly part of Japan’s Mitsubishi Group (now a member of the PHC Corporation Group), to jointly advance the development of ultra‑sensitive cardiac biomarkers and the PATHFAST POCT platform—its bedside chemiluminescent immunoassay system—in China. The fully automated Pathfast point-of-care cardiac biomarker analyzer showcased at this event is widely recognized as the “pioneer” of compact POCT chemiluminescence technology. With its speed, accuracy, and ease of use, this instrument provides robust support for the early diagnosis and timely treatment of cardiac diseases.
Exhibition venue
BIOSINO
At the exhibition, BIOSINO’s professional team enthusiastically introduced the company’s products and technologies to every visitor. With their expert knowledge and sincere attitude, they earned the recognition and praise of numerous customers.
Pooling strengths in science and innovation, we jointly forge a new chapter of health.
BIOSINO
BIOSINO adheres to technological innovation as the cornerstone of its development, aiming for independent breakthroughs in the in vitro diagnostics field. The company continues to deepen the integration of industry and research and translate technological achievements into practical applications, strengthening its integrated competitive advantage of “instruments + reagents + services.” It is committed to building a collaborative and symbiotic industrial innovation ecosystem, demonstrating the sense of responsibility of a national IVD enterprise in the current era. Looking ahead, the company will remain true to its original aspirations and mission, pursue pragmatic action, and continuously refine high-quality, comprehensive clinical diagnostic solutions. By joining forces with industry partners, it will forge ahead together to safeguard public health and realize the vision of a Healthy China.
✦
BIOSINO
✦
BIOSINO Biotechnology Co., Ltd. was founded in 1988 and listed on the Hong Kong Stock Exchange in 2006. It is a high-tech enterprise established by the Institute of Biophysics, Chinese Academy of Sciences, primarily engaged in the R&D, manufacturing, sales, service, and technology transfer of in vitro diagnostic (IVD) products. BIOSINO has been recognized as a “Beijing Enterprise Technology Center” and jointly established the “In Vitro Diagnostic Engineering Research Center” with the Institute of Biophysics, Chinese Academy of Sciences. The company has undertaken numerous national-level scientific and technological projects, including the National “863 Program,” the National Science and Technology Support Program, the National High-Tech Industrial Demonstration Project, and the Chinese Academy of Sciences’ Knowledge Innovation Project—totaling more than ten such initiatives—and has been designated an “Innovative Enterprise” within the Zhongguancun National Independent Innovation Demonstration Zone.
BIOSINO is a member unit of the National Technical Committee for Standardization of Medical Clinical Laboratory and In Vitro Diagnostic Systems (TC136). It has obtained certifications under ISO 13485, the European Union CE mark, South Korea’s KGMP, and Canada’s CMDCAS quality management systems, and has been accredited to ISO/IEC 17025:2017, “General Requirements for the Competence of Testing and Calibration Laboratories.” In March 2025, it received accreditation as a medical reference laboratory from the China National Accreditation Service for Conformity Assessment (CNAS), enabling mutual recognition of reference measurement results internationally. BIOSINO currently operates a production base spanning 16,000 square meters, built in strict compliance with GMP standards. After years of development, BIOSINO has established a comprehensive portfolio of biochemical assay products and expanded into streamlined, immunological, molecular, and POCT in vitro diagnostic product lines, striving to deliver integrated clinical diagnostic solutions.
Customer Service: 010-80117700, 010-64840910
After-sales service: 010-64840919
Previous Page
Previous Page
Other Content
Fax: +86 10 69722840
WhatsApp: +86 138 1003 3479
Email: biosino@zhongsheng.com.cn
Web site: sinobio.com.cn
Office Address: No.27 Chaoqian Road, Changping, Beijing, China, 102200